1. Acknowledgment

   Acknowledgments 11 October 2012 Pages: 1011 - 1013

2. Erratum to: The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK

   • Á Benedict
   • L Verdian
   • G Maclaine

   Erratum 11 October 2012 Pages: 1014 - 1014

3. QALYs and Carers

   • Hareth Al-Janabi
   • Terry N. Flynn
   • Joanna Coast

   Current Opinion 11 October 2012 Pages: 1015 - 1023

4. Modelling the Cost Effectiveness of Treatments for Parkinson’s Disease

   • Judith Dams
   • Bernhard Bornschein
   • Richard Dodel

   Review Article 11 October 2012 Pages: 1025 - 1049

   

5. Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy

   • Rumona Dickson
   • Adrian Bagust
   • Vidhya Sagar Ramani

   Review Article 11 October 2012 Pages: 1051 - 1062

   

6. Cost-Effectiveness Analysis of Prophylactic Lamivudine Use in Preventing Vertical Transmission of Hepatitis B Virus Infection

   • Hui-Fang Hung
   • Hsiu-Hsi Chen

   Original Research Article 11 October 2012 Pages: 1063 - 1073

   

7. Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

   • Helen Dakin
   • Morris Sherman
   • Anthony Bentley

   Original Research Article 11 October 2012 Pages: 1075 - 1091